Rationale for the epidermal growth factor receptor as a target for cancer therapy.
OBJECTIVE
To provide information regarding tumor-specific molecules and signaling pathways responsible for regulation of tumor growth, and review the development of novel targeted therapies that can block the epidermal growth factor receptor (EGFR) at biologically active and less toxic doses compared with standard chemotherapy.


METHODS
Research articles.


CONCLUSIONS
The identification and understanding of novel molecular targets has led to the development of therapeutic agents specific to these targets. Clinical investigations involving EGFR inhibitory agents are being completed. Studies have shown single-agent efficacy and efficacy in combination with chemotherapy and/or radiation therapy.


CONCLUSIONS
Nurses are involved in the administration of targeted therapies. They serve to ensure effective patient education, compliance, and early intervention for toxicities. Knowledge regarding the impact of signaling pathways and the goals of targeted therapy will maximize treatment outcomes for cancer patients.
Wood
Laura S
LS
Cleveland Clinic Foundation, 9500 Euclid Ave, R-33, Cleveland, OH 44195, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004509:Education, Nursing, Continuing; D066246:ErbB Receptors / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000451:nursing*; D015399:Nursing Research; D009859:Oncology Nursing; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D066246:ErbB Receptors